Physician profile
Alyssa Luddy
NPI 1124285572
$641.57
in general payments reported to CMS, 2019-2025
11 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $112 · 2024: $182 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $145.71 | 2024-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $78.62 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $67.03 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $66.91 | 2023-2025 | Acthar |
| Novo Nordisk INC | $61.62 | 2023-2025 | Rivfloza, Ozempic, Rybelsus |
| Ardelyx, INC. | $58.63 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $49.93 | 2025 | |
| Scpharmaceuticals INC. | $42.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $38.18 | 2024-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $17.10 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.61 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Luddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.